[Skip to Navigation]
Sign In
Views 278
Citations 0
Comment & Response
August 19, 2021

Immunochemotherapy as First-line Treatment for Locally Advanced or Metastatic Squamous Non–Small Cell Lung Cancers—Reply

Author Affiliations
  • 1State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
  • 2BeiGene (Beijing) Co, Ltd, Beijing, China
  • 3Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China
JAMA Oncol. 2021;7(10):1580-1581. doi:10.1001/jamaoncol.2021.3375

In Reply We would like to thank Huang et al for their comments regarding our recently published phase 3 randomized clinical trial assessing tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non–small cell lung cancer (NSCLC).1 With regard to the points raised, although a numerical difference in progression-free survival (PFS) was seen when patients with programmed cell death 1 ligand 1 (PD-L1) 1% or greater and PD-L1 less than 1% were compared, interaction analyses did not identify a predictive effect of PD-L1 expression for PFS/objective response rate benefit.1 We were unable to make a concrete conclusion, as our study was not designed to detect the difference between high- and low-expression populations. We agree that these results do not align with those from IMpower131,2 where PFS benefit was observed only in PD-L1–positive subgroups, with greater PFS benefit shown in patients with the highest tumor PD-L1 expression. As mentioned, cross-study comparisons should be approached with caution because many factors, including the assays and methods used to score PD-L1 expression, could drive the differences. As there is no universally accepted definition or standard assay for PD-L1 positivity, integration of PD-L1 expression levels into the treatment of NSCLC is challenging. With a growing body of evidence that suggests PD-L1 expression may play more of a predictive role in patients with nonsquamous vs squamous NSCLC,3 there is a significant need to standardize PD-L1 immunohistochemical detection and integrate it with other emerging biomarker evaluations (eg, gene expression profiling, tumor mutation burden).

Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words